Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 35, 2012, Pages 14164-14169

  Fenton, Tim R ^a,j   Nathanson, David ^b   Ponte De Albuquerque, Claudio ^a   Kuga, Daisuke ^c   Iwanami, Akio ^c   Dang, Julie ^c   Yang, Huijun ^c   Tanaka, Kazuhiro ^c   Oba Shinjo, SueliMieko ^d   Uno, Miyuki ^d   Del Mar Inda, Maria ^a   Wykosky, Jill ^a   Bachoo, Robert M ^e   James, C David ^f   DePinho, Ronald A ^g   Vandenberg, Scott R ^a,h,i   Zhou, Huilin ^a   Marie, Suely K N ^d   Mischel, Paul S ^b,c   Cavenee, Webster K ^a,h,i   Furnari, Frank B ^a,h,i   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Erlotinib; Gefitinib; Glioma; Phosphatase

Indexed keywords

ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; PHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TYROSINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TISSUE; CHROMOSOME 10; CONTROLLED STUDY; ENZYME ACTIVE SITE; GENE DELETION; GENE LOSS; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; ASTROCYTES; BRAIN NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; MICE; MICE, MUTANT STRAINS; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TYROSINE;

ANIMALIA;

EID: 84865542459     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1211962109     Document Type: Article

References (45)

1. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
2. Dey N, et al. (2008) The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68:1862-1871. (Pubitemid 351416572)
3. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK (2005) Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA 102:2703-2706. (Pubitemid 40299856)
4. Shen WH, et al. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128:157- 170.
5. Song MS, et al. (2011) Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 144:187-199.
6. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
7. Furnari FB, et al. (2007) Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21:2683-2710. (Pubitemid 350070717)
8. Haas-Kogan DA, et al. (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887. (Pubitemid 41417939)
9. Mellinghoff IK, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024. (Pubitemid 41609094)
10. Wang X, Jiang X (2008) Post-translational regulation of PTEN. Oncogene 27:5454-5463.
11. Alimonti A, et al. (2010) Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 42:454-458.
12. Koul D, et al. (2002) Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21:2357-2364. (Pubitemid 34407295)
13. Lu Y, et al. (2003) Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278:40057-40066. (Pubitemid 37248572)
14. Nagata Y, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127. (Pubitemid 39485684)
15. Yim EK, et al. (2009) Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15:304-314.
16. Du J, et al. (2009) Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27:77-83.
17. Stettner MR, et al. (2005) Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 65:5535-5543. (Pubitemid 40911153)
18. Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2004) Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 39:29-36. (Pubitemid 37475250)
19. Mohammadi M, et al. (1998) Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17:5896-5904. (Pubitemid 28474784)
20. Stommel JM, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290. (Pubitemid 47574858)
21. Webster MK, D'Avis PY, Robertson SC, Donoghue DJ (1996) Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II. Mol Cell Biol 16:4081-4087. (Pubitemid 26251207)
22. Mahimainathan L, Choudhury GG (2004) Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279:15258-15268. (Pubitemid 38618922)
23. Takahashi Y, Morales FC, Kreimann EL, Georgescu M-M (2006) PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J 25:910-920. (Pubitemid 43292451)
24. Kang S, et al. (2007) FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12:201-214. (Pubitemid 47333416)
25. Kang S, et al. (2008) Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J Biol Chem 283:4652-4657.
26. Furnari FB, Huang HJ, Cavenee WK (1998) The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58:5002-5008. (Pubitemid 28521148)
27. Han SY, et al. (2000) Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 60:3147-3151.
28. Georgescu MM, et al. (2000) Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 60:7033-7038.
29. Lee JO, et al. (1999) Crystal structure of the PTEN tumor suppressor: Implications for its phosphoinositide phosphatase activity and membrane association. Cell 99:323-334.
30. Andrés-Pons A, et al. (2007) In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN. Cancer Res 67:9731-9739.
31. Rodríguez-Escudero I, et al. (2011) A comprehensive functional analysis of PTEN mutations: Implications in tumor- and autism-related syndromes. Hum Mol Genet 20:4132-4142.
32. Rodríguez-Escudero I, et al. (2005) Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem J 390:613-623.
33. de la Iglesia N, et al. (2008) Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 22:449-462.
34. Sarkaria JN, et al. (2007) Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther 6:1167-1174. (Pubitemid 46554588)
35. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, Arteaga CL (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109:2718-2723.
36. Chandarlapaty S, et al. (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71.
37. Ware KE, et al. (2010) Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression. PLoS ONE 5:e14117.
38. Turner N, Grose R (2010) Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10:116-129.
39. Zhang S, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17:461-469.
40. Iijima M, Devreotes P (2002) Tumor suppressor PTEN mediates sensing of chemoattractant gradients. Cell 109:599-610. (Pubitemid 34628723)
41. Janetopoulos C, Borleis J, Vazquez F, Iijima M, Devreotes P (2005) Temporal and spatial regulation of phosphoinositide signaling mediates cytokinesis. Dev Cell 8:467-477. (Pubitemid 40450737)
42. Lindsay Y, et al. (2006) Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 119:5160-5168. (Pubitemid 46085194)
43. Maccario H, Perera NM, Gray A, Downes CP, Leslie NR (2010) Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J Biol Chem 285:12620-12628.
44. Tibarewal P, et al. (2012) PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal 5:ra18.
45. Ishii N, et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469-479. (Pubitemid 29316287)